CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATESPRNewsWire • 08/11/23
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI PharmaceuticalsPRNewsWire • 08/01/23
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339PRNewsWire • 07/20/23
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTSPRNewsWire • 04/26/23
CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINAPRNewsWire • 01/06/23
CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATIONPRNewsWire • 12/15/22
CASI Pharmaceuticals, Inc. (CASI) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/14/22
CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEETPRNewsWire • 09/23/22
ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are BuyingBenzinga • 09/09/22
CASI PHARMACEUTICALS AND BIOINVENT ANNOUNCE DOSING OF FIRST PATIENT IN BI-1206 PHASE 1 CLINICAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY NON-HODGKIN'S LYMPHOMA IN CHINAPRNewsWire • 09/07/22
CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/12/22
CASI Pharmaceuticals, Inc. (CASI) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/12/22
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022PRNewsWire • 08/05/22
CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLIONPRNewsWire • 07/08/22